Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion type Assertion NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_head.
- NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion description "[The utilisation of antitumour T cells induced by cancer vaccination with HER-2 peptides or antibodies (Herceptin) against HER-2, as immunotherapy for oesophageal cancer, is a novel and attractive approach.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_provenance.
- NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion evidence source_evidence_literature NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_provenance.
- NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion SIO_000772 15785739 NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_provenance.
- NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion wasDerivedFrom befree-20140225 NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_provenance.
- NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_assertion wasGeneratedBy ECO_0000203 NP724101.RAArspwfOw_12TnGlr5I5WQMHalQuQGKymoky_ZHlbqbE130_provenance.